Citalopram Dosing Recommendations
Start citalopram at 20 mg once daily for most adults, with a maximum dose of 40 mg/day, but reduce to a maximum of 20 mg/day in patients over 60 years, those with hepatic impairment, or CYP2C19 poor metabolizers due to QT prolongation risk. 1
Standard Adult Dosing (Ages 18-60)
- Initial dose: 20 mg once daily (morning or evening, with or without food) 1
- Titration: Increase to maximum 40 mg/day after at least 1 week if needed 1
- Maximum dose: 40 mg/day 2
- Doses above 40 mg/day are not recommended due to QT prolongation risk, and the 60 mg dose showed no advantage over 40 mg in efficacy studies 1
The 20 mg dose is the minimum effective dose based on meta-analysis of placebo-controlled trials 3, 4. While the dose-response curve is relatively flat between 20-60 mg, patients with severe or recurrent depression may benefit from 40 mg/day 3, 4.
Elderly Patients (>60 Years)
Maximum dose: 20 mg/day 1
- Initial dose: 10 mg/day 2
- Rationale: Citalopram AUC increases by 23-30% and half-life increases by 30-50% in elderly patients 1
- This restriction is primarily due to increased QT prolongation risk in this population 5, 6
The FDA explicitly limits elderly patients to 20 mg/day maximum regardless of response 1. Recent evidence suggests this restriction may be overly conservative as no adverse cardiac outcomes have been directly linked to citalopram in older adults 7, but the FDA guidance remains the standard of care.
Adolescents (12-18 Years)
- Initial dose: 10 mg/day 8
- Titration: Increase by 10 mg increments as tolerated 8
- Effective dose: 20 mg/day 8
- Maximum dose: 60 mg/day 8
Important: Only fluoxetine is FDA-approved for pediatric depression; citalopram use in adolescents is off-label 8. Start at subtherapeutic doses as a "test dose" since SSRIs can initially cause anxiety or agitation 5. Increase slowly at 1-2 week intervals for shorter half-life SSRIs like citalopram 5.
Hepatic Impairment
Maximum dose: 20 mg/day 1
- Citalopram oral clearance is reduced by 37% and half-life doubles in hepatic impairment 1
- Start at 10 mg/day and titrate cautiously 9
- This applies to any degree of hepatic impairment (Child-Pugh A, B, or C) 1
Renal Impairment
- Mild to moderate renal impairment: No dose adjustment needed 1
- Severe renal impairment (CrCl <20 mL/min): Use with caution; no specific dosing data available 1
- Renal clearance accounts for <20% of total citalopram elimination 1, 9
CYP2C19 Poor Metabolizers
Maximum dose: 20 mg/day 1
- CYP2C19 poor metabolizers have 68% higher Cmax and 107% higher AUC 1
- Concomitant CYP2C19 inhibitors (cimetidine, omeprazole): Also limit to 20 mg/day maximum 1
- Coadministration with cimetidine increases escitalopram exposure by 72% 10
Recent PBPK modeling in elderly patients suggests CYP2C19 PMs have 2.1-fold higher exposure than extensive metabolizers, supporting the 10 mg/day dose for this population 11.
Titration and Monitoring
- Titration schedule: Increase in 10 mg increments at intervals of at least 1 week 1
- Adequate trial duration: 4-8 weeks at therapeutic dose 2
- Steady state: Achieved within approximately 1 week of daily dosing 1
- Maintenance therapy: Continue for 4-12 months after first episode; longer for recurrent depression 12
Discontinuation
Taper gradually over 10-14 days to minimize withdrawal symptoms 2, 1. Citalopram has a shorter half-life than fluoxetine and can cause discontinuation syndrome, though less commonly than paroxetine 5.
Critical Safety Considerations
QT Prolongation Risk
- Baseline ECG recommended if risk factors present (cardiac disease, electrolyte abnormalities, concomitant QT-prolonging drugs) 5, 6
- Citalopram causes dose-dependent QT prolongation and is contraindicated with MAOIs 5, 6
- Maximum 40 mg/day in standard adults; 20 mg/day in high-risk groups 1
Drug Interactions
- Avoid with MAOIs: 14-day washout required 1
- Caution with other serotonergic drugs: Risk of serotonin syndrome 5
- Citalopram has minimal CYP450 inhibition compared to other SSRIs, resulting in fewer drug interactions 13, 1
Monitoring in Adolescents
Close monitoring for suicidality is required, especially in the first few months and after dose changes 8. Contact (in-person or telephone) should occur after treatment initiation to assess adherence and adverse events 8.